

## Curriculum Vitae

### Informazioni Generali

**Cognome e nome: Tomassetti Sara**

**Impiegata presso:**  
U.O. Pneumologia  
Ospedale GB Morgagni  
Via C Forlanini 34  
47121 Forlì (FC)  
ITALY

2000	MD, summa cum laude	<u>Laurea</u> Medicina e Chirurgia (Prof G Marchesini)	Bologna University, Italy
------	------------------------	--	------------------------------

**Tirocinio Post-laurea**

2001-2004		Specializzazione	
03/2003-04/2004		Research Fellowship	
2005-2006		Borsa di studio trial clinici IPF	
May 2008; Sept 2009; August 2010; August 2011, May 2012, Nov 2013, Aug 2015		Visiting Clinician Program	

**Attività e posizione funzionale**

2006- ad oggi	Dirigente Medico	U.O. Pneumologia, Dip Toracico	Presidio Ospedaliero GB Morgagni, Forlì, Italy
---------------	------------------	--------------------------------	--

**Altre attività professionali**

2011-ad oggi	Consulente	Intermune-Roche
01/2014-ad oggi	PASSPORT Steering Committee Member	Intermune-Roche
10/2014-ad oggi	Consulente	Boeringher-Inghelheim
15/6/2016-ad oggi	Member of the board of the network	ERN European Network
04/2016-ad oggi	member of the Global IPF Network	University of Colorado, USA

**Società scientifiche**

2010- ad oggi	European Respiratory Society	Membro
2013- ad oggi	European Respiratory Society	ERS Evaluation Committee, Reviewer.
2010- ad oggi	ERS – Interstitial Lung Disease Study group 1.5	Membro
2012 – ad oggi	AIPO – Ass Italiana Pneumologi Ospedalieri	Membro

10/2013-10/2017	AIPO – Ass Italiana Pneumologi Ospedalieri	Responsabile GdS Pneumopatie infiltrative diffuse e patologia del circolo polmonare
-----------------	---	---

### Specifici ambiti di autonomia professionale

2009- 2014	Responsabile percorso IPF	Pulmonary Medicine Unit, GB Morgagni Hospital, Forlì, Italy
2015- ad oggi	Responsabile percorso Malattie Rare e Trapianto Polmonare (Ambulatorio AIMART).	Pulmonary Medicine Unit, GB Morgagni Hospital, Forlì, Italy

All'incirca dal 2009 mi sono dedicate alla creazione ed allo sviluppo dell'ambulatorio dedicato ai pazienti con IPF il cui modello è stato successivamente esteso a tutti i pazienti con malattie rare polmonari, pneumopatie infiltrative diffuse e trapianti. Non essendo Forlì centro trapianti specifica esperienza veniva acquisita presso la Mayo Clinic, Rochester, MN, USA partecipando al Visiting Clinician Program dal 2008 per circa 1 mese all'anno (come specificato nel presente c.v. a pag 2). Il 7/5/2015 veniva acquisito a livello aziendale il nuovo percorso AIMART (Ambulatorio Malattie Rare e Trapianto con creazione del percorso multidisciplinare interaziendale integrato di cui la procedura è allegata al presente c.v.) di cui sono tutt'ora responsabile.

### Attività clinica ed innovazione

#### Abilitazione professionale

1 Giugno 2001      Bologna University, Italy

Iscrizione all'albo dei Medici Chirurghi ed odontoiatri di Forlì, del 4/9/2001, Num 4241

#### Attività pratica svolta

2007-2014	Ambulatorio IPF	Pulmonary Unit, Morgagni Hospital	GB 1-3 giorni a settimana
2015-ad oggi	Ambulatorio Mal rare e trapianti (AIMART)	Pulmonary Unit, Morgagni Hospital	GB 4 giorni a settimana
2007-2014	Attività pneumologia ambulatoria	Pulmonary Unit, Morgagni Hospital	GB Circa 25 settimane /anno

2007-2013	Attività ordinaria	Degenza Pulmonary Unit, Morgagni Hospital	GB	Circa 10 settimane /anno
2007-2013	Attività endoscopica	Pulmonary Unit, Morgagni Hospital	GB	Circa 10 settimane /anno
2015-ad oggi	Attività endoscopica	Pulmonary Unit, Morgagni Hospital	GB	1 giorno a settimana
2007-currently	Attività di reperibilità endoscopica pneumologica	Pulmonary Unit, Morgagni Hospital <sup>e</sup>	GB	Circa 10 turni/mese

**Negli 11 anni di attività clinica svolta presso la U.O. di Pneumologia a Forlì ho potuto acquisire esperienza ed autonomia in tutti i principali ambiti di interesse pneumologico: patologia neoplastica e non neoplastica del torace, patologie ostruttive, tubercolosi, terapia semi-intensiva.**

**Sono stata attivamente coinvolta in attività clinica e di ricerca clinica, ho sviluppato specifiche competenze specialistiche nell'ambito della pneumologia interventistica, delle pneumopatie interstiziali polmonari e dei percorsi di screening trapiantologico e follow-up post trapianto. Sia per la patologia oncologia (Gruppo Interdisciplinare Pneumo-Oncologico) che per la patologia non neoplastica (MDT Pneumologia) ho contribuito alla crescita ed organizzazione dei percorsi integrati multidisciplinari aziendali.**

**Nell'attività endoscopica ho acquisito piena autonomia professionale e specifiche competenze nel campo della broncoscopia rigida e flessibile, dell'utilizzo delle nuove metodiche ecografiche endoscopiche (EBUS/EUS), della toracoscopia medica diagnostica e terapeutica e della criobiopsia transbronchiale, metodica per la quale la Pneumologia di Forlì è leader internazionale.**

#### Innovazioni in ambito clinico

##### **ILD-database.**

Pulmonary Unit; GB  
Morgagni Hospital  
(2005-2016)

In collaborazione con un ing. biomedico ho sviluppato un database e raccolto i dati di più di 600 pazienti IPF (dal 2005 al 12/2016), e di oltre 200 ILD (circa dal 2013 al 2016). L'obiettivo principale era quello di creare uno strumento di semplice utilizzo nella pratica clinica che permettesse di raccogliere dati immediatamente fruibili a scopo di ricerca. Il database è stato utilizzato per raccogliere in modo prospettico tutti i dati clinici dei pazienti. E' stato ampiamente ed efficacemente utilizzato per facilitare gli arruolamenti nei trial clinici. Il database ha permesso la raccolta di dati accurate che sono stati utilizzati in numerose pubblicazioni scientifiche (riportate in sezione pubblicazioni). I dati sono stati presentati a congressi nazionali e internazionali (riportato nelle sezioni relative a alla partecipazione ai congressi).

### Innovazioni tecnologiche

**Transbronchial Cryobiopsy for ILDs diagnosis**  
y Unit; GB Morgagni Hospital (2011-currently)

Il nostro gruppo ha introdotto una nuova metodica di criobiopsia transbronchiale nelle pneumopatie infiltrative diffuse che sostituisce la biopsia polmonare chirurgica riducendo i costi sia in termini di spesa che in termini di rischi di mortalità e complicanze per i pazienti. E' stata una delle più importanti innovazioni in campo endoscopico degli ultimi anni. I risultati sono stati presentati alle riunioni internazionali ERS e ATS dal 2012 ad oggi (presentazioni orali e sessioni di discussione poster) e pubblicate (cfr. Sezione rivista peer rev). La metodica è stata presentata dal nostro gruppo e da massimi esperti internazionali del settore al Clinical year in review in ILDs durante ERS 2016, Clinical Year in review Interventional Pulmonology durante ERS, 2017). Il nostro team ha la più ampia casistica internazionale con oltre 700 casi di ILD ad oggi biopsiate.

**Medical Thoracoscopy**  
Pulmonary Unit; GB Morgagni Hospital (2007-2013)

Faccio toracoscopie dal 2007 nelle patologie pleuriche neoplastiche e non neoplastiche. I risultati della toracosopia medica per il trattamento dell'empima sono stati riportati dal nostro gruppo presso la European Respiratory Society nel 2011 e pubblicati (sezione pubblicazioni).

**EUS/EBUS; \_Pulmonary**  
Unit; GB Morgagni Hospital (2007-2013, 2015-2017)

Sono stata addestrata all'uso dell'EBUS lineare e radiale (40casi/anno) e EUS (5/anno). Abbiamo pubblicato diversi studi su queste metodiche (vedi pubblicazioni)

### **Attività di educazione e supporto ai pazienti**

AMMP Associazione Morgagni per le Malattie Polmonari

2009- currently

Sono uno dei fondatori e membro attivo di questa organizzazione che promuove formazione ed informazione sulla salute in particolare in ambito pneumologico nella comunità locale e supporta programmi di ricerca e didattica nel campo delle malattie rare.

Organizzatrice e promotrice dell'evento intitolato "Il rinforzo della trama", attività educative dedicate alle associazioni dei pazienti e medici locali dal 2014

14/09/2014 " Il rinforzo della trama I ed", Fratta Terme , FC, IT

25/10/2015 " Il rinforzo della trama II ed", Fratta Terme , FC, IT

12/3/2017 " Il rinforzo della trama IIIed", Fratta Terme , FC, IT

### Attività Editoriali

2011	Reviewer	Advances in Therapy
2012- ad oggi	Reviewer	Revista Portuguesa de Pneumologia, Portuguese Journal of Pulmonology
2012- ad oggi	Reviewer	Sarcoidosis Vasculitis and Diffuse Lung Diseases
2012- ad oggi	<b>Member of the Editorial Board and Reviewer</b>	Rassegna di Patologia dell'Apparato Respiratorio
2013	Reviewer	Human Immunology
2013- ad oggi	Reviewer	BMC Pulmonary Medicine
2014- ad oggi	Reviewer	Respirology
2014	Reviewer	Respiratory Research
2015-ad oggi	Reviewer	European Resp Journal
2015	Reviewer	Case Report in Pulmonol.
2017- ad oggi	<b>Member of the Editorial Board</b>	Sarcoidosis Vasculitis and Diffuse Lung Diseases

### Premi Internazionali

6-Dec- 2010	Robalo Cordero Award	26th Congress of Portugese Resp Soc, Coimbra, Portugal	Research Project : "IPF: from environment to genetic"
7-Jun-2013	Poster Award	6th International WASOG Conference in Paris	Poster title "The diagnostic role of TBLC in the MD of IPF".

**Progetti di Ricerca Sponsorizzati**2005-  
2006

INSPIRE TRIAL

NCT00075998

Sub-investigator

Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF

2006-  
2009

CAPACITY TRIAL

NCT00287729

Sub-investigator

The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF) and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.

2008-  
2009

BUILD 3 TRIAL

NCT00391443

Coordinator

BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

2010 ARTEMIS-IPF

NCT00768300

Sub-investigator

Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

**As top enrollers we were audited and successfully completed PPD audit on 16-17 November 2010.**

2010 ARTEMIS-PH

NCT00879229

Sub-investigator

This Phase 3, randomized, double-blind, placebo-controlled, multicenter study will compare the efficacy and safety of ambrisentan to placebo in subjects with pulmonary hypertension associated with idiopathic pulmonary fibrosis

2010-  
2011

RESOLVE

funded by the European  
Commission under  
FP7-HEALTH-F4-2008  
Contract no. 202047

**Study Review Board Member and Subinvestigator**

The basis for all human studies is a combination of careful clinical assessment of disease conditions and sequential analysis of biological data -- to identify relevant molecular targets and separate them from those connected to regular organ repair. Studies relate to lung manifestations of progressive fibrotic disorders of the lung such as IPF and other ILDs.

2011-2012

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464



Sub-investigator

The purpose of this trial is to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.

2011-2014

Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Mechanism and Biomarkers.

E-Rare2 JTC 2011- Funded by European Commission

Sub-investigator

The purpose of this prospective study is to investigate clinical and biomolecular aspects of acute exacerbation of IPF

2012-  
currently  
ongoing

An open label extension trial of the long term safety of oral BIBF 1120 patients with Idiopathic Pulmonary Fibrosis (IPF)

**Principal Investigator**

The primary objective of this study is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow-up period in the phase III trials 1199.32.

Efficacy and Safety of GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (RAINIER)

GS – US – 322-0207

2013- 2016

**Principal Investigator**

A phase 2, randomized, double blind, Placebo – Controlled Multi centre study to assess the efficacy and safety of GS - 6624

2014 – 2016

Safety profile of Esbriet® in patients with IPF and to monitor for any unknown or potential risks of treatment with Esbriet (PASSPORT)

PIPF 025

Sub – Investigator and **Steering Committee Member**

Post – Authorisation Safety Study of Esbriet (Pirfenidone), a prospective observational

Registry to evaluate Long Term Safety in Real World Setting.

2014 -  
ongoing

Efficacy and Safety of LEBRIKIZUMAB in patients with idiopathic pulmonary fibrosis  
GB28547

**Principal Investigator**

A phase II, randomized, double – blind, placebo controlled to assess the efficacy and safety of Lebrikizumab in IPF

PROTOCOL NUMBER: GB28547

EUDRACT NUMBER: 2013-001163-24

2016-  
currently  
enrolling

"IPF Italian Observational Study (FIBRONET) " (Boehringer Ingelheim)

**Principal Investigator**

The primary objective of study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation. In particular, the study aims to provide information on disease characteristics and treatment modalities (at enrolment) and on disease progression.

PROTOCOL NUMBER 1199.262

2016-on  
going

BIBF 1199.36 "A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment" (Boehringer Ingelheim)

**Principal Investigator**

The primary objective of study is evaluating the efficacy and safety of the combination treatment with nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis (IPF) with advanced impairment of lung function.

PROTOCOL NUMBER: 1199.36

EUDRACT NUMBER: 2015-002619-14

2016-on  
going

ML39260 IRENE "An observational, retrospective, multicentre study to evaluate, the efficacy of Pirfenidone administered according to clinical practice to patients with idiopathic

pulmonary fibrosis

**Principal Investigator**

The primary objective is aimed at observing retrospectively clinical progression, in term of lung function and physical endurance at 12 months from the start of treatment, in IPF patients treated with Pirfenidone in accordance with normal clinical practice, at Italian Pneumology centres with expertise in the management of this disease.

PROTOCOL NUMBER : ML39260

2016-on  
going

MA29957 : “ A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Sildenafil added to Pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension.

**Principal Investigator**

The primary efficacy objective for this study is to evaluate the efficacy of adding sildenafil compared with placebo to pirfenidone treatment in patients with advanced IPF and intermediate or high probability of Group 3 PH. The primary efficacy endpoint will be evaluated based on a comparison of the proportion of patients showing disease progression over 52 weeks of treatment period.

PROTOCOL NUMBER : MA29957

EUTRACT NUMBER : 2015-005131-40

2017-on  
going

BIBF 1199.247 “A phase III trial on efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) (PF-ILD)”

**Principal Investigator**

The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated that Nintedanib will be a new treatment option for patients with PF-ILD.

ClinicalTrials.gov Identifier: NCT02999178

Sponsor: Boehringer

MA39189 "A phase III Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease"

**Principal Investigator and National Coordinator Center**

2017-on  
going

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

ClinicalTrials.gov Identifier: NCT03099187

Sponsor: Roche

**Principali progetti di ricerca non sponsorizzati, dal 2010**

2010 The diagnostic role of transbronchial biopsy in UIP

Retrospective, blinded

**Principal Investigator**

Approved Ethics Committee : 22/06/2010 Nr. 1493/2010

(Published)

2010

Pulmonary manifestations of Birt-Hogg-Dubè syndrome

Retrospective Study

**Principal Investigator**

Approved Ethics Committee : 25/08/2010 Nr. 2613/2010

(Published)

2010 Familial Interstitial Pneumonia Profile

Retrospective Study

**Principal Investigator**

Approved Ethics Committee : 26/08/2010 Nr. 2611/2010

(Published, Feb 2014)

2010

Anticoagulant therapy for Idiopathic Pulmonary Fibrosis

Retrospective Study

**Principal Investigator**

Approved Ethics Committee : 29/10/2010 Nr. 3327/2010

(Published )

2011

A simple, clinically relevant staging System for Idiopathic Pulmonary Fibrosis

Retrospective Study

Participating Centre

Approved Ethics Committee : 08/04/2011 Nr. 1385/2011

(Published )

2011

Is Medical Thoracoscopy indicated in the management of Multiloculated and Organized Thoracic Empyema?

Retrospective Study

Co – Investigator

Approved Ethics Committee : 05/09/2011 Nr. 3386/2011

(Published ):

2012

The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis

Retrospective Study

Co – Investigator

Approved Ethics Committee : 26/08/2012 Nr. 2611/2012

(Published)

2012

The diagnostic role of Cryobiopsy in the multidisciplinary diagnosis of fibrotic interstitial lung diseases

Retrospective Study in two steps. Phase one: safety and feasibility. Phase two: MDD.

**Principal Investigator**

Approved Ethics Committee : 27/06/2013 Nr. 3106/2012

(Phase I: published; Phase II :published)

Clinical and prognostic significance of circulating autoantibodies in Idiopathic Pulmonary Fibrosis  
Retrospective Study

2013 **Principal Investigator**

Approved by Ethics Committee

Sleeping Disorders in IPF (DRS in IPF)

Prospective

**Co-PI**

2014 – The purpose of this prospective study is to investigate clinical and physiopathological aspects of sleeping disorders of IPF.

Approved by Ethics Committee

2015 Chest US post criobiopsy for the detection pf PNX

Prospective

**PI**

The purpose is to investiget the role of transthoracic echography in detection of early postprocedural PNX

Approved by EC

### **Presentazioni a Congressi (Ambito Regionale)**

15-16 Sept 2006 Clinical Case - Lymphoproliferative Lung Disorders

Ematologo e Pneumologo Congress – GB Morgagni Hospital, Forlì, ITALY

26-27 Jun 2007 Lung Lymphoproliferative Disorders

Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY

13 Nov 2007 Lymphoproliferative disorders: the role of pulmonologist

Stage in Ematologia: linfomi polmonari, i progressi della conoscenza. Università Studi di Bologna, Bologna ITALY

27-28 Nov 2007 Idiopathic Pulmonary Fibrosis

- 4-8 Feb 2008 Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY  
Idiopathic Pulmonary Fibrosis
- 26-27 Jun 2008 Corso residenziale. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY  
Lung Lymphoproliferative Disorders
- 15-19 Sep 2008 Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY  
Idiopathic Pulmonary Fibrosis
- 25-27 Jan 2010 Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY  
Idiopathic Pulmonary Fibrosis
- 18 May 2010 Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY  
Oxygen therapy in IPF
- 14-16 June 2010 Corso teorico-pratico. Hospice, Forlimpopoli, ITALY  
Idiopathic Pulmonary Fibrosis
- 13-15 Dec 2010 Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY  
Idiopathic Pulmonary Fibrosis, Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
- 1 Dec 2010 Clinical case of Sarcoidosis  
Le Malattie Rare del Polmone. Modena Univeristy, Modena, Forlì ITALY
- 16 Dec 2010 Therapeutic approaches of Idiopathic Pulmonary Fibrosis  
RIPID workshop. Fibrosi ed ipertensione polmonare. GB Morgagni Hospital, Forlì ITALY
- 28-29 Feb 2012 1) La clinica della IPF,  
2) 2) La terapia della IPF.  
Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITALY
- 5-7 March 2012 1) La Fibrosi polmonare Idiopatica

## 3) Le vasculiti

Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY

30 October, 2012 Corso : La Fibrosi Polmonare. GB Morgagni Hospital, Forlì ITALY

19-20 Feb, 2013 1) La clinica della IPF

2) La terapia della IPF

Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITALY

20-22 March,  
2013

1) La Fibrosi polmonare Idiopatica

Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY

10-12 April, 2013

1) La clinica della IPF

2) La terapia della IPF

Corso: le Pneumopatie Infiltrative Diffuse. GB Morgagni Hospital, Forlì ITALY

9 Dec 2013

La Fibrosi polmonare Idiopatica Corso Speed-it. GB Morgagni Hospital, Forlì ITALY

24 Jan  
2014

Diagnosis and treatment of DPLDs. Corso Insuff Respiratoria. Museo Internazionale delle ceramiche, Faenza, ITALY.

27-28 March 2014

IPF, Clinical Ceses presentation. CSI in IPF, Cube Hotel, Ravenna, ITALY.

3-4 Feb, 2015

Clinica della IPF

Corso IPF, Forlì, IT

3-5 March, 2015

Clinica della IPF;

Corso PID, Forlì, IT

PID



10 April, 2015 AIPO giovani, Bologna, IT

5-6 June, 2015 “L’imaging come guida alle procedure endoscopiche”;  
AIPO Pneumo Interventistica; Bologna, IT

13 June, 2015 “New mini invasive diagnostic techniques”; MAR, Modena, IT

15-17 June, 2015 “IPF clinica”; Cosro AIPO PID, Forlì, IT

8-9 Sept, 2015 “A future view on ILD” and “The MDD in ILD diagnosis”;  
Cryobiopsy meeting second ed., Ravenna, IT

18 Sept, 2015 “Clinical case”; Convegno nazionale SIRM, Parma, IT

9-11 Feb, 2016 “Clinica della IPF e dintorni”  
Fibrosi Polmonare Idiopatica. Forlì, FC, IT

9-10 June  
2014 The role of TBLC in MD diagnosis of IPF. Transbronchial lung cryobiopsy. ERS endorsed  
course. Ravenna, Italy

7-9 June, 2016 “Fibrosi polmonare idiopatica: clinica” e “Procedure diagnostiche invasive”  
Corso Pneumopatie infiltrative diffuse. GB Morgagni H, Forlì, FC, IT

3-4 and 24-25 May, 2016 In Hospital Meeting: IPF Excellence. Forlì IT

- 3 May, “Il profilo clinico della IPF”
- 4 May “La terapia della IPF”
- 25 May “La criobiopsia polmonare”

28-19 Oct, 2016 “Treatment of IPF : an update”  
TBLC in DPLD. Endorsed by ERS. Ravenna, IT

21 Oct, 2016 Meet the Expert in IPF. Forli, FC, IT

- “Opzioni terapeutiche nel trattamento dell’IPF”
- “Casi clinici multidisciplinari: dalla diagnosi alla cura del paziente con IPF – Esperienze a confronto”
- “Stars e Black Holes: successi e problematiche irrisolte dei Centri di riferimento. Modelli e risultati organizzativi dei Centri e problematiche gestionali”

19 Oct, 2016 “Ottimizzare la gestione del paziente con BPCO” ECM 38-164989. Forli, Italy

3 Nov, 2016 “La visione del clinico”

“FARMACISTI A CONFRONTO: APPROPRIATEZZA TERAPEUTICA, BUDGET DI SPESA E GESTIONE DELLE GARE” Rimini, IT

13-14 Dec, 2016 “La diagnosi differenziale”

LA CONDIVISIONE DELLA PRATICA CLINICA NELLA FIBROSI POLMONARE IDIOPATICA. 9 national centres web-connected. Forli, IT.

14-16 Feb, 2017 “Profili clinici IPF e quasi IPF” e “Early IPF and IPF friends perchè e quando trattare” IPF and friends. Forli, IT

8-9 Maggio, 2017 Speaker:

- “Opzioni terapeutiche”
- “Aspetti organizzativi nella gestione del paziente” Tavola rotonda Clinical management of IPF, Ravenna, IT

20-21 June, 2017 Speaker: “IPF” and Chair of the session “Patologia sistemica I” Corso Pneumopatie infiltrative diffuse, Forli, IT

#### **Corsi e Lezioni tenute nell’ambito di progetti educazionali sponsorizzati**

3-5 June 2014 Perceptorship. International training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forli, Italy

- 13-15 Oct 2014      **INSIDE IPF.** National training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forlì, Italy
- 20-2 Oct 2014      **Perceptorship.** International training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forlì, Italy
- 11-12 Nov, 2014      Global internal train the trainer meeting, for pharma industry representatives, sponsored by Boeringher-Inghelheim. Frankfurt, Germany.
- Nov-Dec, 2015      “In-Hospital” and “Tutorship” programs, for pharma industry representatives sponsored by Boeringher-Inghelheim, GB Morgagni Hospital, Forlì, IT.
- 4 Nov 2015      “Regional Lab”, Forlì, FC, IT. Educational program for pharmacists sponsored by Boeringher-Inghelheim
- 15 Dec, 2015      “Call Simulation”, Educational program for pharmacists sponsored by Boeringher-Inghelheim Bologna, IT
- 12-14 Jan, 201      “In-Hospital” program for pharma industry representatives sponsored by Boeringher-Inghelheim, GB Morgagni Hospital, Forlì, IT.
- 23-25 Nov, 2016      **Perceptorship.** International training program for chest physicians on IPF sponsored by Roche. GB Morgagni Hospital, Forlì, Italy
- 10 e 31 Maggio, 2017      Consultant , speaker and tutor in the Sliding Doors program for pulmonologists, held in Padova, IT Sponsored by Roche

#### **Presentazioni a Congressi (Ambito Nazionale)**

- 20-22 Oct 2008      Usual Interstitial Pneumonia  
Advanced Course. HRCT of the thorax. Arezzo, ITALY
- 2-5 Dec 2009      1) Idiopathic Pulmonary Fibrosis  
2) Anti TNF treatment for ILDs-related to connective tissue diseases.

## 3) Birt Hogg Dubè Syndrome

AIPPO National Pulmonary Congress, Milan Convention Center, ITALY

- 19 June 2009      Diagnosis of ILDs  
 Aggiornamenti in Med Interna. Bari, ITALY
- 15-17 April 2010      1) Clinical profile of diseases with HRCT Reticular Patterns  
                                  2) Clinical Cases  
 Corso teorico-pratico. Interstiziopatie polmonari. Gubbio, ITALY
- 10-12 May 2010      Idiopathic Pulmonary Fibrosis  
 ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
- 25-26 Nov 2010      Birt Hogg Dubè Syndrome, the pulmonologist point of view  
 Giornata di Informazione sulla sindrome di Birt Hogg Dubè. Az Osp S Croce Carle, Cuneo, ITALY
- 4-6 April 2011      Practical approaches to Idiopathic Pulmonary Fibrosis  
 ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
- 30Nov-3Dec 2011      Evoluzione e storia naturale delle pneumopatie interstiziali - IPF e cancro  
 XII National Congress UIP, Bologna, ITALY
- 26-28 March, 2012      Clinical differential aspects of IPF.  
 ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY
- 12-14 April, 2012      Fibrosi Polmonare Idiopatica : la clinica.  
 Le pneumopatie infiltrative diffuse: nuove acquisizioni. Villanovaforru, Cagliari.
- 3-5 May 2012      Le PID con pattern reticolare

- 26-27 Oct, 2012 III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.  
Pirfenidone Named Patient Program.  
AIR Meeting Italia. Rome, Italy.
- 8-10 April, 2013 Different clinical profiles of IPF.  
ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY
- 17 April, 2013 La clinica delle interstiziopatie polmonari.  
Corso di patologia pleuro-polmonare. Dipartimento Anatomia Patologica, Università degli Studi di Verona, Italy.
- 27 April, 2013 Criobiopsia  
Sorrento Breathing, Sorrento, Italy.
- 7-9 Maggio, 2013 La IPF: la clinica  
Pneumopatie infiltrative diffuse, asma e BPCO. Villanovaforru, Cagliari, ITALY
- 28-29 June, 2013 L'esperienza NPP in Italia: cosa abbiamo imparato.  
AIR MEETING ITALIA 2013. Milano, Italy.
- 7-9 April 2014 Idiopathic Pulmonary Fibrosis, clinical aspects  
ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
- 7-8 June 2014 Novel Therapies for IPF. Asthma, IPF and other ILDs. Assisi, ITALY
- 27-28 June, 2014 IPF, mystery case  
AIR MEETING ITALIA 2014. Rome, Italy.
- 1-3 oct, 2014 Update on ILD  
FIP, National Pulmonology Congress, Genova, Italy.

- 8-11 Sept ,2014 La clinica delle interstiziopatie polmonari.  
PneumoCampania 2014 - 7<sup>a</sup> edizione Vietri sul Mare, Italy.
- 23-25 Oct 2014 Clinical cases on ILDs  
III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.
- 28-29 Nov, 2014 "Clinica e terapia della IPF;" Updates in Pneumologia, Cosenza, Italy
- 5-6 Nov, 2014 Staging e FU della IPF, IPF workshop, Palermo, Italy
- 7-8 Nov, 2014 "IPF aspetti clinici e terapeutici"; Convegno interregionale ASPAM Terni, IT
- 14-15 Nov, 2014 "Diagnosi della IPF con tecniche invasive"; AIPO Toscana, Massa Carrara, IT
- 5-6 Feb 2015 "Le metodiche invasive"; Orizzonti in pneumologia, Verona, IT
- 13-15 April 2015 "PPFE, NSIP, HP"; Pneumotrieste 2015, Trieste, IT
- 9 May, 2015 "Grande fornitore di UIP"; 20anni di trapianto, Padova, IT
- 29-30 May, 2015 "DIAGNOSIS OF PULMONARY FIBROSIS, WHAT'S NEW?";  
the Missing Links, Roma, IT
- 25-26 June, 2015 "End point dei trial clinici nella IPF, cosa migliorare"; Air meeting Italia, Roma, IT
- 2 Oct, 2015 "Clinical case"; LA DIAGNOSI MULTIDISCIPLINARE E LE SCELTE TERAPEUTICHE  
DELLE PID e IPF; Firenze, IT
- 9-10 Oct, "IPF:an heterogeneous entity"; AIPO Lazio, Nemi, Roma, IT
- 16-17 Oct, "IPF profile clinic e stadiazione"; IPF next generation, Matera, IT
- 19 Oct, 2015 "IPF"; Confidence, Trieste, IT
- 6 Nov, 2015 "I misteri delle malattie dell'interstizio polmonare ed i segreti del ventricolo destro"

San Daniele del Friuli, Udine, IT

11-15 Nov, 2015 AIPO, Annual National Congress. Naples, IT:

- 12 Nov, “Highlights dalle recenti linee guida/raccomandazioni nazionali ed internazionali”
- 13 Nov, “Common Variable Immunodeficiency”
- 14 Nov, “IPF treatment”

11, Dec 2015 “Biopsia per via endoscopica o chirurgica?”  
Pneumoroma Annual Congress. Roma, IT

12, Dec 2015 “UIP il punto sul Pirfenidone e le nuove terapie”  
Updates in Pneumologia. Mendicino, CS, IT

21—22 Jan, 2016 “La fibrosi polmonare idiopatica: patogenesi e terapia”  
Bari Pneumologica. Bari, IT

18-20 Feb, 2016 “Lo Pneumologo: il nuovo documento AIPO-SIMeR”  
Il futuro della pneumologia...la pneumologia del future. Lecce, IT

12-13 April, 2016 “New frontiers. Early IPF”  
ERS course DPLD. Respiro Trieste. Trieste, IT

14-15 April, 2016 “La terapia medica della fibrosi polmonare idiopatica: passato, presente e futuro”  
Aggiornamento sulle patologie polmonari. Taranto, IT

16 April, 2016 “Biomarkers: quale utilità ai fini diagnostici, prognostici e di risposta alle terapie”  
Innovazione ed organizzazione in pneumologia. Matera, IT

20 April, 2016 “Attualità in tema di IPF”  
Congresso sez regionle AIPO ER. Baggiovara, Modena, IT

28-30 April, 2016 “Le Infezioni disseminate”  
Le pneumopatie interstiziali diffuse. Gubbio, IT

6 May, 2016 “Dagli elementi anatomo-patologici all’Imaging. Quali certezze per il clinico?”  
Col fiato corto 6. Palermo, IT

27 May, 2016 “Fibrosi e granulomatosi polmonare da droghe”  
11° Pneumosalento. Lecce, IT

17-18 June, 2016 “Terapia dell’IPF”

La criobiopsia nella patologia parenchimale diffusa. Genova, IT

23-25 June, 2016 “I marcatori di patologia nell’IPF: molecolari, funzionali, clinico-radiologici”

AIR Meeting National. Baveno, IT

7-8 Oct, 2016 “La gestione diagnostica dei casi “difficili” e il ricorso alla biopsia: quando è necessaria una diagnosi istologica e come eseguirla”.

Le pneumopatie infiltrative diffuse. Chieti, IT

8 Nov, 2016 “Criobiopsia

La patologia toracica di interesse chirurgico e medico: le convergenze parallele. Verona, IT

11 Nov, 2016 “Nuove linee guida nazionali ed internazionali della IPF: similitudini differenze”

AIPO regione Marche. Civitanova Marche, IT

15-17 Dec, 2016

“Markers molecolari della IPF e dei suoi mimickers”

Pneumoroma. Roma, IT

2-3 Feb, 2017

“La terapia della NSIP”

Orizzonti in Pneumologia. Verona, IT

31 March-1 April, 2017 Il trattamento «ritardato» nell’IPF è ancora accettabile? Oxford Debate

AIR Meeting Italia, Bologna, IT

3-5 April, 2017

“ILA prevalence and clinical relevance”

ERS course DPLD. Respiro Trieste. Trieste, IT

26-27 Maggio, 2017 Speaker: “La criobiopsia nella diagnosi delle PID”

S.S.D.PNEUMOLOGIA Settore Aggiornamento e Formazione  
INTERNATIONAL CONGRESS, Courmayeur, Aosta IT

10-13 June, 2017

Speaker: “PID Acute” 12 June

Chair: “ Granulomatosi polmonari” 13 June

AIPO, National Congress of Italian Pulmonology, Bologna, IT

16-17 June, 2017

Speaker: “Pattern fibrosante: quando è IPF”, and clinical cases presentation



Fibrosing lung diseases a MD approach, Ancona , IT

**Presentazioni a Congressi Internazionali**

- 24 May 2012 Genetic determinants of Familial Pulmonary Fibrosis.  
Developmental Pulmonology Laboratory Research Conference. Department of Pediatrics, S Francisco General Hospital, UCSF, CA, USA.
- 30Nov-1Dec, 2012 Interactive Clinical Cases. Working together to translate IPF research into practice.  
European AIR Meeting, Rome, Italy.
- 5 June 2013 The role of TBLC in the multidisciplinary diagnosis of IPF.  
Wasog Meeting. Paris, France\*  
**\*Recipient of the Wasog Best Poster Presentation Award**
- 19-21 June 2014 The pathogenesis of NSIP.  
Fibrosing Interstitial Lung Dis of idiopathic and exogenous origin. Prague, Czech Rep
- 6-10 Sept 2014 Patient cases: the multidisciplinary approach  
Evening Symposium : How to diagnose and treat IPF: learnings from clinical and real-world experience  
ERS annual congress. Munich. Germany
- 27 Sept, 2015 “Educational skills workshop: EW10 Radiological – pathological correlations for clinicians”; Workstation 2: Interstitial fibrosis;  
ERS annual Congress, Amsterdam, Netherlands
- 27 Nov, 2015 “MDT case in Session 2: Striving for early IPF diagnosis”  
Air Meeting International. Prague, CZ
- 12 March, 2016 Transbronchialcryobiopsy in ILD, overview and update

presented with Prof. T.V. Colby, Mayo Clinic ,AZ  
USCAP Annual Meeting, Seattle, WA, USA

16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update  
Pulmonary Fellow Wednesday Morning Meeting, Mayo Clinic ,AZ

16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update  
Pulmonary Metting, Phoenix Hospital, AZ

8-11 May, 2016 “Multidisciplinary diagnosis”  
World Congress for Bronchology and Interventional Pulmonology. Florence, IT

1-4 June, 2016 8th international WASOG conference. Gdnask, Poland

- Transbronchial cryobiopsy in diffuse parenchymal lung diseases
- Case presentation clinical round

2-7 Sept 2016 ERS Annual Congress. London, UK

- Skills workshop: SW20 Radiological-pathological correlations for clinicians.  
Workstation 2: Interstitial fibrosis
- Year in review: Clinical year in review Diffuse parenchymal lung disease. Session 518

17-19 Nov, 2016 “ BLC for the diagnosis of IPF”  
Advancing IPF Research (AIR) Educational Meeting. Vienna.

22 Feb, 2017 “ Transbronchial lung cryobiopsy in idiopathic interstitial pneumonia: state of the art “  
Workshop: a new era for IP. Leuven, Belgium

23 Feb, 2017 “Clinical diagnostic value of bronchoscopy in IIP “  
Interventional Pulmonology symposium. Leuven, Belgium

9-13 Sept, 2017 - Speaker and tutor: "Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation 2: Interstitial fibrosis  
ERS, Milan, IT

**Altre attività nell'ambito di Congressi Internazionali (ultimi 5 anni)**

Date and Location	Course/Activity
24-28 Sept, 2011	European Respiratory Society Annual Meeting Amsterdam, The Netherlands <b>Co-chair for Thematic Poster Session</b> entitled: Rare diffuse lung diseases
19-23 May, 2012	ATS Annual Meeting, San Francisco, CA, USA, May 2012. <b>Poster Presentation</b> Abstract 30968 "Transbronchial biopsy is a useful mini-invasive sampling method to detect UIP pattern".
1-5 Sept, 2012	European Respiratory Society Annual Meeting <b>Co-chair for Poster Discussion Session:</b> idiopathic pulmonary fibrosis.
7-11 September, 2013	European Respiratory Society Annual Meeting <b>Co-chair Thematic Poster Session</b> entitled: Diffuse parenchymal lung disease II <b>Chair Poster Discussion Session</b> entitled: Idiopathic pulmonary fibrosis and rarities
26-30 Sept, 2015	European Respiratory Society Annual Meeting <b>30/9/2015 Chair Poster Discussion</b> entitled: New insight into IIPs <b>30/9/2015 Chair Oral Presentation</b> entitled: IPF clinical aspects II
8-11 May, 2016	2016 World Congress for Bronchology and Interventional Pulmonology. Florence, IT <b>Chair Poster Discussion</b> session "Bronchoscopy in TB and diffuse lung diseases. BAL and cryo biopsy"
2-7 Sept 2016	ERS Annual Congress. London, UK <b>coChair Thematic Poster:</b> Clinical aspects of ILD T10 session 174

9-13 Sept, 2017 - **Chair : Oral session** “gastrointestinal diseases and lung” and **Chair Thematic poster session** “ILDs: clinical aspects”

ERS, Milan, IT

## Produzione Scientifica

### Tesi di Specialità in Malattie dell'Apparato Respiratorio

Tesi sostenuta il 27/10/2004 – Modena and Reggio Emilia University, Modena, ITALY

Titolo "A possible immunological role for dendritic cells in chronic obstructive lung disease pathogenesis: the antigen presentation process may be influenced by an impairment of their migratory ability caused by MMP12 and others MMPs/MMPs inhibitors expression imbalance".

Principal Investigator: Prof. SD Shapiro, Respiratory and Critical Care Medicine, Harvard University, Boston, MA, USA

Chair: Prof. LM Fabbri, Respiratory Medicine, Modena and Reggio Emilia University, Modena, Italy

### Publicazioni scientifiche (peer reviewed)

#### Research investigations (\*equal contribution)

1. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, **Tomassetti S**, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017 Aug 31;50(2).
2. Bosi M, Milioli G, Fanfulla F, **Tomassetti S**, Ryu JH, Parrino L, Riccardi S, Melpignano A, Vaudano AE, Ravaglia C, Tantalocco P, Rossi A, Poletti V. OSA and Prolonged Oxygen Desaturation During Sleep are Strong Predictors of Poor Outcome in IPF. *Lung*. 2017 Jul 3.
3. Viglietta L, Inchingolo R, Pavano C, **Tomassetti S**, Piciucchi S, Smargiassi A, Ravaglia C, Dubini A, Gurioli C, Gurioli C, Poletti V. Ultrasonography for the Diagnosis of Pneumothorax after Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases. *Respiration*. 2017;94(2):232-236.
4. Calìo A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, **Tomassetti S**, Piciucchi S, Nottegar A, Rossi G, Kambouchner M, Cancellieri A, Barbareschi M, Pelosi G, Doglioni C, Cavazza A, Carella R, Graziano P, Murer B, Poletti V, Chilosi M. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. *Histopathology*. 2017 May 30.

5. Mariani F, Gatti B, Rocca A, Bonifazi F, Cavazza A, Fanti S, **Tomassetti S**, Piciucchi S, Poletti V, Zompatori M. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. *Diagn Interv Radiol*. 2016 Jul 26.
6. **Tomassetti S**, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, Sverzellati N, Carloni A, Carretta E, Buccioli M, Tantalocco P, Ravaglia C, Gurioli C, Dubini A, Piciucchi S, Ryu JH, Poletti V. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2016 Apr 1;193(7):745-52.
7. Ravaglia C, Bonifazi M, Wells AU, **Tomassetti S**, Gurioli C, Piciucchi S, Dubini A, Tantalocco P, Sanna S, Negri E, Tramacere I, Ventura VA, Cavazza A, Rossi A, Chilosi M, La Vecchia C, Gasparini S, Poletti V. Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. *Respiration*. 2016;91(3):215-27.
8. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, **Tomassetti S**, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. *Respir Med*. 2015 Jul;109(7):904-13.
9. **Tomassetti S\***, Gurioli C\*, Ryu J, Decker P, Ravaglia C, Tantalocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A, Gavelli G, Chilosi M, Poletti V. The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis. *Chest*. 2015 Jan;147(1):157-64.
10. Ravaglia C, **Tomassetti S**, Gurioli Ch, Piciucchi S, Dubini A, Gurioli C, Casoni GL, Romagnoli M, Carloni A, Tantalocco P, Buccioli M, Poletti V. Features and outcome of familial idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2014 Apr 18;31(1):28-36.
11. GL Casoni\*, **S Tomassetti\***, A Cavazza, TV Colby, A Dubini, JH Ryu, E Carretta, P Tantalocco, S Piciucchi, C Ravaglia, C Gurioli, M Romagnoli, C Gurioli, M Chilosi, V Poletti. Transbronchial Lung Cryobiopsy in The Diagnosis of Fibrotic Interstitial Lung Diseases *PLoS One*. 2014 Feb 28;9(2):e86716.
12. Chilosi M, Facchetti F, Calio A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, **Tomassetti S**, Poletti V, Doglioni C. Oncogene induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans' cell histiocytosis. *Leuk Lymphoma*. 2014 Jan 29.
13. Ulivi P, Casoni GL, Foschi G, Scarpi E, **Tomassetti S**, Romagnoli M, Ravaglia C, Mengozzi M,

- Zoli W, Poletti V. MMP-7 and free circulating DNA serum levels in early NSCLC and idiopathic interstitial pneumonia patients. *Int J Mol Sci.* 2013 Dec 11;14(12):24097-112.
14. S. Tomassetti, J.H. Ryu, C. Gurioli, C. Ravaglia, M. Buccioli, P. Tantalocco, P.A. Decker, A. Cavazza, A. Dubini, V. Agnoletti, C. Gurioli, G.L. Casoni, M. Romagnoli, V. Poletti The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice. *Sarcoidosis Vasc Diffuse Lung Dis.* 2013 Aug 1;30(2):121-127.
  15. Ravaglia C, Tomassetti S, Gurioli C, Buccioli M, Tantalocco P, Derni S, Maltoni M, Poletti V. Palliative medicine and end-of-life care in idiopathic pulmonary fibrosis. *J Palliat Med.* 2013 Apr;16(4):339.
  16. Tomassetti S, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciocchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. Transbronchial biopsy is useful in predicting UIP pattern. *Respir Res.* 2012 Oct 29;13:96
  17. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med.* 2012 May 15;156(10):684-91.
  18. Piciocchi S, Tomassetti S, Casoni G, Sverzellati N, Carloni A, Dubini A, Gavelli G, Cavazza A, Chilosi M, Poletti V. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. *Respir Res.* 2011 Aug 23;12:111.
  19. Casoni GL, Cordeiro CR Jr, Tomassetti S, Romagnoli M, Chilosi M, Cancellieri A, Gurioli C, Poletti V. The transbronchial lung biopsy for diagnosis of diffuse parenchymal lung disease: Rev Port Pneumol. 2011 Jun 28.
  20. Tomassetti S, Carloni A, Chilosi M, Maffè A, Ungari S, Sverzellati N, Gurioli C, Casoni G, Romagnoli M, Gurioli C, Ravaglia C, Poletti V. Pulmonary features of Birt-Hogg-Dubé syndrome: cystic lesions and pulmonary histiocytoma. *Respir Med.* 2011 May;105(5):768-74. Epub 2011 Feb 26.
  21. Romagnoli M, Nannini C, Piciocchi S, Girelli F, Gurioli C, Casoni G, Ravaglia C, Tomassetti S, Gurioli C, Gavelli G, Carloni A, Dubini A, Cantini F, Chilosi M, Poletti V. Idiopathic NSIP: an interstitial lung disease associated with autoimmune disorders? *Eur Respir J.* 2011 Jan 27.
  22. Reghellin D, Poletti V, Tomassetti S, Dubini A, Cavazza A, Rossi G, Lestani M, Pedron S, Daniele I, Montagna L, Murer B, Chilosi M. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2010 Jul;27(1):57-63.
  23. Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers.* 2010 Oct-Dec;25(4):229-35.

24. Maffé A, Toschi B, Circo G, Giachino D, Giglio S, Rizzo A, Carloni A, Poletti V, Tomassetti S, Ginardi C, Ungari S, Genuardi M. Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations. Clin Genet. 2010 Jun 7.
25. Sverzellati N, Wells AU, Tomassetti S, Desai SR, Copley SJ, Aziz ZA, Zompatori M, Chilosi M, Nicholson AG, Poletti V, Hansell DM. Biopsy proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin section CT diagnoses. Radiology. 2010 Mar;254(3):957-64
26. G Marchesini, M Brizi, G Bianchi, S Tomassetti, E Bugianesi, M Lenzi, S Natale, AJ Mc Cullough, G Forlani, N Melchionda. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50:1844-50

**a. Other peer-reviewed publications (review, case reports and case series, report of new methods, guidelines and consensus documents)**

27. Piciucchi S, Tomassetti S, Colby TV, Poletti V. Role of fibrogenesis of gastroesophageal reflux and microaspiration in a patient with 12 years of radiologic follow-up. Hum Pathol. 2017 Jan;59:152-153.
28. Tomassetti S. PID e circolo polmonare. Correvva l'anno 2016. Rassegna Mal App Resp, 2017
29. Tomassetti S, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. Eur Respir Rev. 2017 Apr 26;26(144).
30. Bosi Ravaglia Tomassetti Gurioli Colinnelli Nardi Poletti La sidrome delle apnee ostruttive nel sonno nel paziente con stroke rassegna vol 31 p 14-18 2016
31. Piciucchi S, Dubini A, Tomassetti S, Sanna S, Ravaglia C, Carloni A, Gurioli C, Gurioli C, Colby TV, Poletti V. Angiosarcoma in the chest: radiologic-pathologic correlation: Case report. Medicine (Baltimore). 2016 Nov;95(48):e5348.
32. Piciucchi S, Tomassetti S, Colby TV, Poletti V. Role of fibrogenesis of gastroesophageal reflux and microaspiration in a patient with 12 years of radiologic follow-up. Hum Pathol. 2017 Jan;59:152-153.
33. Colby TV, Tomassetti S, Cavazza A, Dubini A, Poletti V. Transbronchial Cryobiopsy in Diffuse Lung Disease: Update for the Pathologist. Arch Pathol Lab Med. 2017 Jul;141(7)
34. Varone F, Mastrobattista A, Franchi P, Viglietta L, Poletti V, Tomassetti S, Dubini A, Tagliaboschi L, Calandriello L, Farchione A, Larici AR. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. Clin Respir J. 2016 Jun 20. doi: 10.1111/crj.12515.
35. Piciucchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli C, Dubini A, Carloni A, Chilosi M, Colby TV, Poletti V. From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology? BMC Pulm Med. 2016 May



23;16(1):87.

36. **Tomassetti S**, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management? *Semin Respir Crit Care Med*. 2016 Jun;37(3):378-94.
37. **Poletti V**, Ravaglia C, Gurioli C, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Rossi A, **Tomassetti S**. Invasive diagnostic techniques in idiopathic interstitial pneumonias. *Respirology*. 2016 Jan;21(1):44-50.
38. **Tomassetti S**, Ryu JH, Poletti V. Staging systems and disease severity assessment in interstitial lung diseases. *Curr Opin Pulm Med*. 2015 Sep;21(5):463-9.
39. Milioli G, Bosi M, Poletti V, **Tomassetti S**, Grassi A, Riccardi S, Terzano MG, Parrino L. Sleep and respiratory sleep disorders in idiopathic pulmonary fibrosis. *Sleep Med Rev*. 2016 Apr;26:57-63.
40. **Colella S**, Clementsen PF, Gurioli C, Gurioli CH, Ravaglia C, Tomassetti S, Rossi A, Piciucchi S, Dubini A, Poletti V. Endobronchial-ultrasound needle aspiration and endoscopic ultrasound-fine-needle aspiration in thoracic diseases. *Pathologica*. 2016 Jun;108(2):59-79.
41. Poletti V, Ravaglia C, **Tomassetti S**. Transbronchial cryobiopsy in diffuse parenchymal lung diseases. *Curr Opin Pulm Med*. 2016 May;22(3):289-96.
42. **S Tomassetti**. Correvva l'anno 2015, pneumopatie infiltrative diffuse e patologia del circolo polmonare. *Rassegna di Patologia dell'Apparato Respiratorio*, 2016
43. Pietrangeli V, Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Cavazza A, Dubini A, Poletti V. Diffuse Neuroendocrine Hyperplasia with Obliterative Bronchiolitis and Usual Interstitial Pneumonia: An Unusual "Headcheese Pattern" with Nodules. *Lung*. 2015 Oct 7. [Epub ahead of print]
44. Antoniou KM, **Tomassetti S**, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. *Curr Opin Pulm Med*. 2015 Nov;21(6):626-33.
45. **Tomassetti S**, Piciucchi S, Tantalocco P, Dubini A, Poletti V. The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review. *Eur Respir Rev*. 2015 Mar;24(135):69-77.
46. Piciucchi S, Dubini A, **Tomassetti S**, Casoni G, Ravaglia C, Poletti V. A case of amiodarone-induced acute fibrinous and organizing pneumonia mimicking mesothelioma. *Am J Respir Crit Care Med*. 2015 Jan 1;191(1):104-6.

47. Sara Tomassetti, Carlo Albera Domenico Aronne Marco Confalonieri Sergio Harari Maurizio Luisetti Venerino Poletti Luca Richeldi Paola Rottoli Cesare Saltini Carlo Vancheri Patrizio Vitulo. Alberto Pesci. Documento AIPO-SIMeR sulla IPF. Rassegna di Mal App Resp, 2015
48. S Tomassetti. Correvia l'anno 2014, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2015
49. Poletti V, Ravaglia C, Tomassetti S. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Expert Rev Respir Med.* 2014 Oct;8(5):539-45.
50. V Poletti, GL Casoni, C Gurioli, JH Ryu, S Tomassetti. Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy? *Respirology.* 2014 Jul;19(5):645-54.
51. S Tomassetti. Correvia l'anno 2013, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2014
52. KM. Antoniou, GA. Margaritopoulos, Sara Tomassetti, F Bonella, U. Costabel and V. Poletti. INTERSTITIAL LUNG DISEASE: Year In Review. *Eur Respir Rev.* 2014 Mar 1;23(131):40-54.
53. V Poletti, C Ravaglia, S Tomassetti, C Gurioli, G Casoni, S Ascoli, A Dubini, S Piciocchi, M Chilosi Lymphoproliferative lung disorders: clinicopathologic aspects. *Eur Respir Rev.* 2013 Dec;22(130):427-36.
54. S Tomassetti, JH. Ryu, G Casoni, C Gurioli, C Ravaglia, M Buccioli, P Tantalocco, C. Gurioli M Romagnoli, V Poletti. Revisione critica delle Linee Guida ATS/ERS sulla fibrosi polmonare idiopatica (IPF). Critical revision of ATS / ERS Guidelines on idiopathic pulmonary fibrosis (IPF). *Rassegna di Patologia dell'Apparato Respiratorio* 2013; 28: 74-89
55. Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciocchi S, Dubini A, Carloni A, Chilosi M, Tomassetti S. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. *Respiration.* 2013;86(1):5-12.
56. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax.* 2012 Nov;67(11):938-40.
57. Ravaglia C, Gurioli C, Tomassetti S, Casoni GL, Romagnoli M, Gurioli C, Agnoletti V, Poletti V. Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema? *Respiration.* 2012;84(3):219-24.
58. J.H. Ryu, F. Maldonado and S. Tomassetti Idiopathic tracheopathies. *Eur Respir Mon* 2011. 54, 1–15.
59. Gurioli C, Ravaglia C, Romagnoli M, Casoni G, Tomassetti S, Nanni O, Poletti V EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series. *Clin Respir J.* 2012 Jan;6(1):3-8.
60. Casoni GL, Chilosi M, Romagnoli M, Tomassetti S, Poletti V. Another "chance" for interferon gamma 1b? *Sarcoidosis Vasc Diffuse Lung Dis.* 2011 Jul;28(1):79-80

61. Poletti V, Casoni G, Ravaglia C, Romagnoli M, **Tomassetti S**. Bronchoalveolar lavage. Technical notes. *Monaldi Arch Chest Dis*. 2011 Mar;75(1):42-3.
62. Gurioli C, Casoni GL, Gurioli C, **Tomassetti S**, Romagnoli M, Ravaglia C, Poletti V. Endobronchial ultrasound in Dieulafoy's disease of the bronchus: an additional application of EBUS. *Monaldi Arch Chest Dis*. 2010 Dec;73(4):166-8.
63. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica*. 2010 Dec;102(6):443-52.
64. Ravaglia C, Gurioli C, Casoni G, Romagnoli M, **Tomassetti S**, Gurioli C, Corso RM, Poletti G, Dubini A, Marinou A, Poletti V. Diagnostic role of rapid on-site cytologic examination (ROSE) of broncho-alveolar lavage in ALI/ARDS. *Pathologica*. 2012 Apr;104(2):65-9.
65. Ryu JH, **Tomassetti S**, Maldonado F. Update on uncommon pleural effusions. *Respirology*. 2010 Nov 15.
66. Poletti V, **Tomassetti**. Ultrasound endoscopy (EBUS, EUS) as a sophisticated tool for morphological confirmation of sarcoidosis: do we need to find new answers for an old quest? *S. Sarcoidosis Vasc Diffuse Lung Dis*. 2010 Jul;27(1):5-6.
67. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica*. 2010 Dec;102(6):443-52.
68. Casoni GL, **Tomassetti S**, Coffa A, Ravaglia C, Poletti V. Negative pressure pulmonary hemorrhage induced by a candy. *Am J Emerg Med*. 2010 Jan;28(1):112.
69. De Filippo, Ingegnoli A, Carloni A, Verardo E, Sverzellati N, Onniboni M, Corsi A, **Tomassetti S**, Mazzei M, Volterrani L, Poletti V, Zompatori M. Erdheim-Chester disease: clinical and radiological findings. *Diagnostic Radiology . Radiol Med*. 2009 Nov 14.
70. Romagnoli M, Bigliuzzi C, Casoni GL, Chilosi M, Carloni A, Dubini A, Gurioli Ch, **Tomassetti S**, Gurioli C, Poletti V. "The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients". *Sarcoidosis, Vasculitis and Diffuse Lung Diseases*, 2008.
71. Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, **Tomassetti S**, Broccoli A, Derenzini E, Baccarani M. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. *Clin Lymphoma Myeloma*. 2007 Nov;7(9):566-72.

- **Letters to the Editor**

1. Ravaglia C, Gurioli C, Casoni GL, Romagnoli M, **Tomassetti S**, Gurioli C, Dubini A, Poletti V. Sarcoid-like lesion is a frequent benign cause of lymphadenopathy in neoplastic patients. *Eur Respir J*. 2013 Mar;41(3):754-5.
2. G.Marchesini,M.Brizi,G.Bianchi,**S.Tomassetti**,M.Zoli,N.Melchionda. Metformin in non-alcoholic steatohepatitis. *Lancet* 2001; 358:893-4

- **Books/Textbooks for the medical or scientific community**

1. Gurioli, S. Tomassetti, C. Gurioli Applicazioni dell'ecografia endobronchiale alla broncoscopia terapeutica. In Poletti V. and Ceron L. Diagnostica ed interventistica ultrasonografica endoscopica. Edizioni minerva Medica, 2014.
2. Poletti V, Zinzani PL, Tomassetti S, Chilosi M. Lymphoproliferative Lung Disorders. In : Costabel U, Du Bois RM, Egan JJ (Eds). Diffuse Parenchymal Lung Disease. Progr Respir Res, Basel, Karger 2007:307-322.

#### Research publications without named authorship

Clinton S. Robbins, Francesca Franco, Majd Mouded, Manuela Cernadas, Steven D. Shapiro (Tomassetti S cited in the Acknowledgments section). Cigarette Smoke Exposure Impairs Dendritic Cell Maturation and T Cell Proliferation in Thoracic Lymph Nodes of Mice. J Immunol. 2008 May 15; 180(10): 6623–6628.

#### Non-peer reviewe publications

1. Tomassetti S<sup>1</sup>, Ravaglia C<sup>1</sup>, Gurioli C<sup>1</sup>, Chiappalone G<sup>1</sup>, Poletti V<sup>1</sup>. Prognostic assessment in IPF. Shortness of Breath, 2015
2. S. Tomassetti. Il fumo di sigaretta e la fibrosi polmonare idiopatica [Cigarettes smoke and IPF]. In: Nuovi Orizzonti. Editor: AIPO Ricerche 2008.
3. S Tomassetti. Fibrosi polmonare Idiopatica: attuali e future prospettive terapeutiche. Lung Forum, Workbook di aggiornamento in pneumologia, Sept 2014

<b>Indici citazioni</b>	Tutte	Dal 2012
Citazioni	4804	2669
Indice H	22	21
i10-index	33	33

\* Google Scholar 16 Sept 2017

#### ENGLISH LANGUAGE PROFICIENCY CERTIFICATE

#### IELST

BRITISH COUNCIL, Bologna, 18<sup>th</sup> January 2014

Candidate Number 11435; Passport Number AA2422927

**Results: LISTENING 8.0; READING 8.5; WRITING 7; SPEAKING 7; OVERALL 7.5.**